FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann (Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 […]